SC
Sio Capital Management, LLC
13F filer · CIK 0001482416Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$604MU.S. long equity reported on 13F
Positions5714 new · 30 closed
Net flow last quarter-$234MBuys minus sells
Top 10 positions weight48.4%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202657 positions | |||||
| $54.6M | 9.04% | 5.69% | +3.0% | Q4 2024 | |
| $49.1M | 8.13% | 0.09% | +72.1% | Q2 2018 | |
| $38.5M | 6.36% | 1.37% | -7.0% | Q3 2024 | |
| $27.7M | 4.59% | 3.86% | New | Q2 2026 | |
| $23.8M | 3.95% | 0.22% | Not reported | Q1 2017 | |
| $22.9M | 3.79% | 0.01% | +13.2% | Q4 2014 | |
| $22.2M | 3.68% | 1.17% | +14.8% | Q1 2022 | |
| $19M | 3.15% | 0.48% | -43.6% | Q4 2025 | |
| $17.9M | 2.96% | 0.50% | Not reported | Q2 2020 | |
| $16.9M | 2.79% | 0.29% | +33.7% | Q4 2025 | |
| $15.9M | 2.63% | 0.02% | Not reported | Q2 2015 | |
| $15.5M | 2.57% | 0.03% | +52.0% | Q4 2014 | |
| $15.3M | 2.53% | 0.11% | -71.2% | Q3 2017 | |
| $15.2M | 2.51% | 0.08% | Not reported | Q4 2024 | |
| CCCCRNCross Country Healthcare Inc | $14.5M | 2.40% | 3.40% | Not reported | Q2 2019 |
| $12.8M | 2.12% | 0.64% | -16.1% | Q3 2025 | |
| $11.7M | 1.93% | 0.01% | -31.0% | Q2 2016 | |
| $11.5M | 1.90% | 0.22% | -43.2% | Q3 2025 | |
| $11.3M | 1.87% | 0.07% | +109.9% | Q4 2015 | |
| $11.2M | 1.86% | 0.02% | Not reported | Q3 2019 | |
| $11.1M | 1.85% | 0.01% | Not reported | Q3 2015 | |
| $11.1M | 1.84% | 0.01% | Not reported | Q2 2015 | |
| $11M | 1.81% | 0.64% | -28.3% | Q4 2024 | |
| $9.05M | 1.50% | 3.01% | +1275.6% | Q3 2018 | |
| $8.91M | 1.47% | 0.73% | -13.7% | Q1 2026 | |
| $8.59M | 1.42% | 2.52% | New | Q2 2026 | |
| $8.05M | 1.33% | 0.43% | -63.4% | Q4 2021 | |
| $7.34M | 1.21% | 3.25% | -2.4% | Q4 2024 | |
| $6.94M | 1.15% | 0.94% | +4.0% | Q4 2022 | |
| $6.52M | 1.08% | 0.12% | New | Q2 2026 | |
| $6.18M | 1.02% | 1.18% | -22.7% | Q1 2025 | |
| $5.78M | 0.96% | 0.11% | -84.0% | Q1 2025 | |
| $5.62M | 0.93% | 0.28% | -56.6% | Q1 2026 | |
| $5.3M | 0.88% | 0.25% | -44.3% | Q2 2019 | |
| $5.29M | 0.88% | 0.33% | -37.1% | Q1 2026 | |
| $5.19M | 0.86% | 0.97% | -14.1% | Q4 2024 | |
| $4.92M | 0.81% | 2.67% | Not reported | Q1 2026 | |
| $3.8M | 0.63% | 0.30% | +0.6% | Q2 2019 | |
| $3.53M | 0.58% | 4.93% | -14.4% | Q3 2020 | |
| $3.16M | 0.52% | 0.17% | Not reported | Q2 2021 | |
| $2.7M | 0.45% | 0.54% | -19.7% | Q4 2019 | |
| $2.63M | 0.44% | 0.11% | -24.8% | Q1 2026 | |
| $2.56M | 0.42% | 1.46% | -19.4% | Q1 2026 | |
| $1.94M | 0.32% | 3.94% | Not reported | Q1 2026 | |
| $1.89M | 0.31% | 5.25% | Not reported | Q1 2025 | |
| $1.58M | 0.26% | 1.62% | Not reported | Q4 2025 | |
| $1.46M | 0.24% | 2.32% | Not reported | Q4 2025 | |
| $1.09M | 0.18% | 0.10% | Not reported | Q3 2024 | |
| $995K | 0.16% | 0.16% | Not reported | Q3 2025 | |
| $477K | 0.08% | 1.42% | Not reported | Q4 2024 | |
| Q1 2026Reported May 14, 202673 positions | |||||
| $49.3M | 7.07% | 1.45% | +53.7% | Q3 2024 | |
| $39.6M | 5.68% | 0.86% | +167.6% | Q4 2025 | |
| $33.9M | 4.86% | 0.40% | +140.8% | Q3 2017 | |
| $31.7M | 4.55% | 0.05% | +534.6% | Q2 2018 | |
| $31.1M | 4.45% | 0.68% | -22.0% | Q1 2025 | |
| $29.9M | 4.28% | 5.54% | +187.2% | Q4 2024 | |
| $27.2M | 3.90% | 0.63% | New | Q1 2026 | |
| $26.8M | 3.84% | 0.77% | +30.8% | Q4 2025 | |
| $23.2M | 3.33% | 1.02% | +15.1% | Q1 2022 | |
| $22.1M | 3.17% | 0.40% | -59.4% | Q3 2025 | |
| $21.3M | 3.05% | 0.01% | Not reported | Q4 2014 | |
| $20.4M | 2.93% | 1.18% | +204.3% | Q4 2021 | |
| $19.2M | 2.75% | 0.01% | Not reported | Q2 2016 | |
| $16.3M | 2.34% | 3.11% | Not reported | Q3 2023 | |
| $15.1M | 2.17% | 0.17% | +214.9% | Q4 2025 | |
| $13.4M | 1.93% | 0.93% | +213.3% | Q4 2024 | |
| $12.4M | 1.78% | 0.49% | +138.2% | Q1 2025 | |
| $11.8M | 1.69% | 0.65% | New | Q1 2026 | |
| $11.5M | 1.66% | 0.02% | -75.3% | Q4 2014 | |
| $11.5M | 1.65% | 0.77% | +98.0% | Q3 2025 | |
| $11.3M | 1.63% | 0.21% | +9.1% | Q3 2023 | |
| $11M | 1.57% | 0.10% | -16.5% | Q3 2020 | |
| CCCCRNCross Country Healthcare Inc | $10.3M | 1.48% | 3.52% | +2.8% | Q2 2019 |
| $10.3M | 1.47% | 3.58% | +14.8% | Q4 2024 | |
| $10.1M | 1.45% | 0.10% | +3.8% | Q4 2025 | |
| $9.85M | 1.41% | 0.77% | -6.5% | Q2 2022 | |
| $9.51M | 1.36% | 2.59% | New | Q1 2026 | |
| $9.3M | 1.33% | 0.86% | New | Q1 2026 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $9.08M | 1.30% | 0.24% | +100.2% | Q3 2025 |
| $8.47M | 1.22% | 0.25% | +13.3% | Q2 2025 | |
| $8.33M | 1.19% | 1.12% | Not reported | Q4 2023 | |
| $8.2M | 1.18% | 0.44% | Not reported | Q2 2019 | |
| $7.98M | 1.14% | 1.55% | +93.6% | Q1 2025 | |
| $6.72M | 0.96% | 0.92% | Not reported | Q4 2022 | |
| $6.5M | 0.93% | 0.26% | +12.2% | Q4 2025 | |
| $6.49M | 0.93% | 0.53% | New | Q1 2026 | |
| $6.28M | 0.90% | 1.13% | +5.1% | Q4 2024 | |
| $5.9M | 0.85% | 0.53% | New | Q1 2026 | |
| $5.66M | 0.81% | 0.03% | -83.8% | Q4 2015 | |
| $5.51M | 0.79% | 0.87% | New | Q1 2026 | |
| $5.19M | 0.74% | 0.33% | -74.7% | Q4 2021 | |
| $4.47M | 0.64% | 7.89% | New | Q1 2026 | |
| $4.17M | 0.60% | 0.17% | +13.2% | Q2 2024 | |
| $3.81M | 0.55% | 5.77% | +16.7% | Q3 2020 | |
| $3.61M | 0.52% | 0.15% | New | Q1 2026 | |
| $3.61M | 0.52% | 0.49% | Not reported | Q1 2024 | |
| $3.35M | 0.48% | 0.30% | Not reported | Q2 2019 | |
| $3.17M | 0.45% | 1.86% | -9.7% | Q1 2021 | |
| $3.06M | 0.44% | 1.02% | -7.6% | Q3 2025 | |
| $2.78M | 0.40% | 0.75% | -12.3% | Q4 2019 | |
| Q4 2025Reported Feb 17, 202665 positions | |||||
| $47.6M | 7.48% | 0.99% | -39.4% | Q3 2025 | |
| $47.4M | 7.46% | 0.07% | Not reported | Q2 2015 | |
| $47.1M | 7.41% | 0.08% | +72.7% | Q4 2014 | |
| $43.2M | 6.79% | 0.92% | -10.3% | Q3 2024 | |
| $34.7M | 5.45% | 0.19% | Not reported | Q4 2015 | |
| $25.3M | 3.98% | 0.08% | +73.6% | Q2 2024 | |
| $24.5M | 3.86% | 1.31% | Not reported | Q4 2021 | |
| $23.2M | 3.65% | 0.17% | Not reported | Q3 2017 | |
| $20.1M | 3.16% | 0.32% | New | Q4 2025 | |
| $19.8M | 3.12% | 0.59% | New | Q4 2025 | |
| $19.6M | 3.08% | 1.10% | -17.9% | Q1 2025 | |
| $14.1M | 2.21% | 0.94% | Not reported | Q2 2022 | |
| $14M | 2.20% | 0.09% | New | Q4 2025 | |
| $13.8M | 2.18% | 0.12% | +3.4% | Q3 2020 | |
| $13.8M | 2.18% | 0.98% | +2.2% | Q1 2022 | |
| $11.5M | 1.81% | 0.16% | New | Q4 2025 | |
| $11.3M | 1.78% | 0.06% | -29.2% | Q1 2021 | |
| $11M | 1.73% | 0.11% | New | Q4 2025 | |
| $10.6M | 1.67% | 0.20% | +116.9% | Q3 2023 | |
| $9.35M | 1.47% | 4.51% | +5.8% | Q4 2024 | |
| $9.14M | 1.44% | 3.20% | Not reported | Q4 2024 | |
| CCCCRNCross Country Healthcare Inc | $8.66M | 1.36% | 3.37% | Not reported | Q2 2019 |
| $7.42M | 1.17% | 0.20% | -53.2% | Q1 2025 | |
| $6.89M | 1.08% | 0.39% | +56.6% | Q4 2021 | |
| $6.42M | 1.01% | 0.81% | -33.7% | Q1 2025 | |
| $6.39M | 1.01% | 1.07% | -57.1% | Q4 2024 | |
| $5.89M | 0.93% | 0.22% | -22.7% | Q2 2025 | |
| $5.82M | 0.91% | 0.05% | New | Q4 2025 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $5.81M | 0.91% | 0.13% | -28.6% | Q3 2025 |
| $5.62M | 0.88% | 0.39% | Not reported | Q3 2025 | |
| $5.37M | 0.84% | 0.01% | Not reported | Q2 2018 | |
| $5.25M | 0.83% | 0.01% | Not reported | Q4 2015 | |
| $4.57M | 0.72% | 0.15% | -79.8% | Q2 2024 | |
| $4.37M | 0.69% | 2.05% | +4.3% | Q1 2021 | |
| $4.32M | 0.68% | 0.57% | Not reported | Q4 2020 | |
| $3.7M | 0.58% | 0.30% | -15.5% | Q2 2019 | |
| $3.58M | 0.56% | 0.24% | New | Q4 2025 | |
| VBVTYXVentyx Biosciences, Inc. | $3.5M | 0.55% | 0.54% | -53.2% | Q1 2024 |
| $3.3M | 0.52% | 4.94% | Not reported | Q3 2020 | |
| $3.26M | 0.51% | 1.11% | -34.9% | Q3 2025 | |
| $3.13M | 0.49% | 5.44% | Not reported | Q1 2025 | |
| $2.88M | 0.45% | 0.34% | Not reported | Q4 2024 | |
| $2.67M | 0.42% | 0.06% | -85.9% | Q1 2020 | |
| $2.62M | 0.41% | 0.09% | -39.0% | Q2 2020 | |
| $2.51M | 0.39% | 0.04% | New | Q4 2025 | |
| $2.33M | 0.37% | 1.10% | Not reported | Q4 2019 | |
| $1.97M | 0.31% | 1.46% | Not reported | Q2 2024 | |
| $1.96M | 0.31% | Not reported | New | Q4 2025 | |
| $1.64M | 0.26% | 0.16% | Not reported | Q3 2025 | |
| $1.43M | 0.22% | 2.46% | New | Q4 2025 | |
| Q3 2025Reported Nov 13, 202551 positions | |||||
| $50.9M | 12.89% | 1.02% | +1.7% | Q3 2024 | |
| $38.9M | 9.83% | 1.82% | New | Q3 2025 | |
| $26.6M | 6.72% | 0.04% | +200.1% | Q4 2014 | |
| $22.7M | 5.75% | 1.35% | +144.7% | Q1 2025 | |
| $20.2M | 5.12% | 0.41% | Not reported | Q1 2020 | |
| $18.8M | 4.76% | 0.81% | Not reported | Q2 2024 | |
| $14.9M | 3.77% | 0.01% | +1.9% | Q1 2015 | |
| $14.5M | 3.68% | 0.18% | New | Q3 2025 | |
| $13.8M | 3.50% | 0.08% | +47.7% | Q1 2021 | |
| $13.7M | 3.47% | 0.04% | Not reported | Q2 2024 | |
| $12.2M | 3.09% | 0.12% | Not reported | Q3 2020 | |
| $11.6M | 2.94% | 0.01% | Not reported | Q4 2014 | |
| $11.6M | 2.93% | 2.50% | -62.8% | Q4 2024 | |
| $9.65M | 2.44% | 0.42% | Not reported | Q1 2025 | |
| $8.37M | 2.12% | 1.23% | +58.1% | Q1 2025 | |
| KPKALVKalVista Pharmaceuticals, Inc. | $8.33M | 2.11% | 1.35% | New | Q3 2025 |
| $7.98M | 2.02% | 4.92% | -3.6% | Q4 2024 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $7.28M | 1.84% | 0.18% | New | Q3 2025 |
| $7.2M | 1.82% | 0.97% | -36.5% | Q1 2022 | |
| $5.5M | 1.39% | 0.39% | New | Q3 2025 | |
| $5.35M | 1.35% | 0.37% | New | Q3 2025 | |
| $5.1M | 1.29% | 0.26% | -50.7% | Q4 2021 | |
| $4.98M | 1.26% | 0.29% | -43.1% | Q2 2025 | |
| $4.9M | 1.24% | 0.09% | Not reported | Q3 2023 | |
| $4.83M | 1.22% | 1.59% | New | Q3 2025 | |
| $4.42M | 1.12% | 1.97% | Not reported | Q1 2021 | |
| $4.39M | 1.11% | 1.70% | New | Q3 2025 | |
| $3.69M | 0.93% | 4.98% | -29.4% | Q3 2020 | |
| $3.56M | 0.90% | 0.42% | -67.6% | Q4 2024 | |
| $3.38M | 0.86% | 0.14% | Not reported | Q2 2020 | |
| $3.29M | 0.83% | 5.46% | Not reported | Q1 2025 | |
| $2.99M | 0.76% | 0.48% | Not reported | Q1 2024 | |
| $2.73M | 0.69% | 0.34% | Not reported | Q4 2024 | |
| $2.59M | 0.66% | 0.42% | Not reported | Q2 2019 | |
| VBVTYXVentyx Biosciences, Inc. | $2.58M | 0.65% | 1.16% | -36.6% | Q1 2024 |
| $2.1M | 0.53% | 28.32% | -33.0% | Q2 2025 | |
| $1.86M | 0.47% | 2.01% | -36.0% | Q4 2019 | |
| $1.51M | 0.38% | 0.16% | New | Q3 2025 | |
| $1.3M | 0.33% | 1.46% | Not reported | Q2 2024 | |
| $1.01M | 0.26% | 5.67% | -52.3% | Q3 2018 | |
| $948K | 0.24% | 1.58% | Not reported | Q4 2024 | |
| $917K | 0.23% | 0.40% | Not reported | Q1 2024 | |
| $601K | 0.15% | 0.22% | Not reported | Q4 2023 | |
| $550K | 0.14% | 1.28% | Not reported | Q2 2022 | |
| $234K | 0.06% | 0.14% | Not reported | Q3 2021 | |
| $201K | 0.05% | 0.73% | Not reported | Q1 2024 | |
| $166K | 0.04% | 1.88% | -59.8% | Q1 2023 | |
| TPTERNTerns Pharmaceuticals, Inc. | $75.9K | 0.02% | 0.01% | Not reported | Q3 2024 |
| $64.1K | 0.02% | 0.41% | 0.0% | Q4 2021 | |
| $14.4K | 0.00% | Not reported | Not reported | Q1 2023 | |
Premium opens every quarter this fund has filed